The test detects early albumin markers in urine within 10 minutes, targeting high-risk diabetes and hypertension patients.
The United Arab Emirates (UAE) Ministry of Health and Prevention has approved Biomerica Inc’s Fortel Kidney Test for home use, expanding access to early kidney disease detection in high-risk populations.
The rapid diagnostic test detects low levels of albumin, a critical early marker of kidney disease, in urine within 10 minutes. The approval specifically targets populations with diabetes and hypertension, two leading risk factors for kidney disease that affect significant portions of the UAE population.
According to the company, diabetes affects approximately one in four UAE nationals, while hypertension prevalence reaches about 31% overall, with higher rates in men (43.9%) compared to women (34.5%). Both conditions often remain undiagnosed until significant kidney damage occurs.
“The Fortel Kidney Test addresses a gap in preventative healthcare by allowing patients and physicians to detect kidney disease before symptoms appear,” says Zack Irani, CEO of Biomerica, in a release. “With the high prevalence of diabetes and hypertension in the UAE, this approval supports our mission to bring life-saving diagnostic tools to communities where they are most needed.”
Market Distribution and Clinical Impact
The Fortel Kidney (Microalbumin) Test will be available through partnerships with distributors and healthcare providers in pharmacies, clinics, and hospitals throughout the UAE. The approval strengthens Biomerica’s Middle East presence, following regional success with its EZ Detect Colon Disease Test and other diagnostic products. The company has focused on developing point-of-care and home-use diagnostics for gastrointestinal and inflammatory diseases.
Biomerica develops, manufactures, and markets diagnostic and therapeutic products for point-of-care use in homes and physicians’ offices, as well as hospital and clinical laboratory settings. The company holds patents on its diagnostic technologies and focuses on products designed to reduce total healthcare costs while enhancing patient outcomes.
ID 67864040 © Ben Schonewille | Dreamstime.com
